RE:RE:From Friday's BNN Broadcast
Focus on the message, not the messenger.
1. The gravy train for pharma M&A as a vehicle for growth is over sector wide
2. CXR does not have the money for more acquisition. The large acquisition it made is eating them from the inside.
3. They have no pipeline. The 60 new products is "reformulation" taking an old pill and making itto a liquid or gel capsule.
4. The NHS is on to the "game" of reformulation with all the media attention and they likely feel they have been "played". Bureaucrats hate that. You want to "wake them up"? Make them look stupid in public. They sets the and/or enforce the rules. If get bureaucrats get mad they can make the life of companies very hard "opps, sorry, that request you sent in, we can't find it, are you sure you sent it. Never received. Send and we'll put it in the queue. Make sure you call us to ensure we have it, ok?"
5. They are not able to pay the $200M due to Cinven for AMCo, and given the last quarter note that performance of the AMCo (International division) was higher than expected, the earnout liability could be much more because it's "performance based". Drugs were jacked up right before the transaction from Cincen to Concordia.
I feel for shareholders here. I was one. Please research. We have all been fooled. I know by who. Do you?